These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 7525957

  • 21. Vascular damage and lack of angiogenesis in systemic sclerosis skin.
    Konttinen YT, Mackiewicz Z, Ruuttila P, Ceponis A, Sukura A, Povilenaite D, Hukkanen M, Virtanen I.
    Clin Rheumatol; 2003 Sep; 22(3):196-202. PubMed ID: 14505210
    [Abstract] [Full Text] [Related]

  • 22. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis.
    Hamaguchi Y, Fujimoto M, Matsushita T, Hasegawa M, Takehara K, Sato S.
    J Rheumatol; 2008 Dec; 35(12):2363-71. PubMed ID: 19004037
    [Abstract] [Full Text] [Related]

  • 23. Circulating Vdelta1+ T cells are activated and accumulate in the skin of systemic sclerosis patients.
    Giacomelli R, Matucci-Cerinic M, Cipriani P, Ghersetich I, Lattanzio R, Pavan A, Pignone A, Cagnoni ML, Lotti T, Tonietti G.
    Arthritis Rheum; 1998 Feb; 41(2):327-34. PubMed ID: 9485091
    [Abstract] [Full Text] [Related]

  • 24. [Expression and distribution of type I, III and V collagens in skin lesions from patients with systemic sclerosis].
    Liu T, Zhang J.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):748-52. PubMed ID: 19024305
    [Abstract] [Full Text] [Related]

  • 25. Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse.
    Ong VH, Evans LA, Shiwen X, Fisher IB, Rajkumar V, Abraham DJ, Black CM, Denton CP.
    Arthritis Rheum; 2003 Jul; 48(7):1979-91. PubMed ID: 12847692
    [Abstract] [Full Text] [Related]

  • 26. The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis.
    Davies CA, Jeziorska M, Freemont AJ, Herrick AL.
    Hum Pathol; 2006 Feb; 37(2):190-7. PubMed ID: 16426919
    [Abstract] [Full Text] [Related]

  • 27. Upregulated expression of transforming growth factor-beta receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis.
    Kubo M, Ihn H, Yamane K, Tamaki K.
    J Rheumatol; 2002 Dec; 29(12):2558-64. PubMed ID: 12465152
    [Abstract] [Full Text] [Related]

  • 28. Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications.
    Cipriani P, Franca Milia A, Liakouli V, Pacini A, Manetti M, Marrelli A, Toscano A, Pingiotti E, Fulminis A, Guiducci S, Perricone R, Kahaleh B, Matucci-Cerinic M, Ibba-Manneschi L, Giacomelli R.
    Arthritis Rheum; 2006 Sep; 54(9):3022-33. PubMed ID: 16948134
    [Abstract] [Full Text] [Related]

  • 29. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels.
    Polisson RP, Gilkeson GS, Pyun EH, Pisetsky DS, Smith EA, Simon LS.
    J Rheumatol; 1996 Apr; 23(4):654-8. PubMed ID: 8730122
    [Abstract] [Full Text] [Related]

  • 30. Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis.
    Taniguchi T, Asano Y, Akamata K, Noda S, Masui Y, Yamada D, Takahashi T, Ichimura Y, Toyama T, Tamaki Z, Tada Y, Sugaya M, Kadono T, Sato S.
    J Rheumatol; 2012 Mar; 39(3):539-44. PubMed ID: 22247367
    [Abstract] [Full Text] [Related]

  • 31. Endothelin-1 does not change the function of monocyte-derived dendritic cells grown from patients with systemic sclerosis.
    Slobodin G, Pavlotzky E, Panov J, Rosner I, Kessel A, Toubi E.
    Immunol Invest; 2008 Mar; 37(8):841-8. PubMed ID: 18991099
    [Abstract] [Full Text] [Related]

  • 32. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon.
    Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaran R, Black C.
    Arthritis Rheum; 1994 Feb; 37(2):278-88. PubMed ID: 7510487
    [Abstract] [Full Text] [Related]

  • 33. Detection of activated complement complex C5b-9 and complement receptor C5a in skin biopsies of patients with systemic sclerosis (scleroderma).
    Sprott H, Müller-Ladner U, Distler O, Gay RE, Barnum SR, Landthaler M, Schölmerich J, Lang B, Gay S.
    J Rheumatol; 2000 Feb; 27(2):402-4. PubMed ID: 10685805
    [Abstract] [Full Text] [Related]

  • 34. Variations of neuronal nitric oxide synthase in systemic sclerosis skin.
    Ibba-Manneschi L, Niissalo S, Milia AF, Allanore Y, Del Rosso A, Pacini A, Manetti M, Toscano A, Cipriani P, Liakouli V, Giacomelli R, Kahan A, Konttinen YT, Matucci-Cerinic M.
    Arthritis Rheum; 2006 Jan; 54(1):202-13. PubMed ID: 16385516
    [Abstract] [Full Text] [Related]

  • 35. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis.
    Yanaba K, Muroi E, Yoshizaki A, Hara T, Ogawa F, Shimizu K, Yozaki M, Hasegawa M, Fujimoto M, Takehara K, Sato S.
    J Rheumatol; 2009 Sep; 36(9):1917-23. PubMed ID: 19605674
    [Abstract] [Full Text] [Related]

  • 36. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation.
    Carulli MT, Ong VH, Ponticos M, Shiwen X, Abraham DJ, Black CM, Denton CP.
    Arthritis Rheum; 2005 Dec; 52(12):3772-82. PubMed ID: 16320328
    [Abstract] [Full Text] [Related]

  • 37. Evidence of 5-lipoxygenase overexpression in the skin of patients with systemic sclerosis: a newly identified pathway to skin inflammation in systemic sclerosis.
    Kowal-Bielecka O, Distler O, Neidhart M, Künzler P, Rethage J, Nawrath M, Carossino A, Pap T, Müller-Ladner U, Michel BA, Sierakowski S, Matucci-Cerinic M, Gay RE, Gay S.
    Arthritis Rheum; 2001 Aug; 44(8):1865-75. PubMed ID: 11508440
    [Abstract] [Full Text] [Related]

  • 38. Aberrant expression of membrane cofactor protein and decay-accelerating factor in the endothelium of patients with systemic sclerosis. A possible mechanism of vascular damage.
    Venneker GT, van den Hoogen FH, Boerbooms AM, Bos JD, Asghar SS.
    Lab Invest; 1994 Jun; 70(6):830-5. PubMed ID: 7516986
    [Abstract] [Full Text] [Related]

  • 39. Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.
    Yanaba K, Komura K, Kodera M, Matsushita T, Hasegawa M, Takehara K, Sato S.
    Ann Rheum Dis; 2006 Jan; 65(1):124-6. PubMed ID: 16344498
    [Abstract] [Full Text] [Related]

  • 40. In situ expression and serum levels of tumor necrosis factor-alpha receptors in patients with early stages of systemic sclerosis.
    Gruschwitz MS, Albrecht M, Vieth G, Haustein UF.
    J Rheumatol; 1997 Oct; 24(10):1936-43. PubMed ID: 9330935
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.